Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PONTIAC study of trastuzumab deruxtecan versus CDK4/6 inhibitor-based endocrine therapy in first-line HR-positive HER2-low/ultralow advanced non-luminal breast cancer
2024-512360-55-00Phase 2Authorised
- Sponsor
- MEDSIR
- Start
- Jun 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of trastuzumab deruxtecan, abemaciclib, palbociclib, ribociclib, fulvestrant and 5 more in breast cancer (2 arms), sponsored by MEDSIR. Primary endpoints: Progression-free survival in HER2-low population and Progression-free survival in all patients. Planned start Jun 2025; status: authorised.
02
Drugs
trastuzumab deruxtecanabemaciclibpalbociclibribociclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-512360-55-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512360-55-00.